Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Green Thumb Industries Inc. GTBIF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
80/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$17.00
+137.4%

Green Thumb Industries Inc. (GTBIF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $7.16. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Analyst consensus target is GTBIF = $17 (+137.4% upside).

Financials: revenue is $1.2B, +4.9%/yr average growth. Net income is $116M, growing at +121.1%/yr. Net profit margin is 9.9% (thin). Gross margin is 48.9% (-0.6 pp trend).

Balance sheet: total debt is $517M against $1.9B equity (Debt-to-Equity (D/E) ratio 0.27, conservative). Current ratio is 1.55 (strong liquidity). Debt-to-assets is 18.5%. Total assets: $2.8B.

Analyst outlook: 5 / 5 analysts rate GTBIF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 93/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 63/100 (Partial), Future 100/100 (Pass), Income 45/100 (Partial).

$17.00
▲ 137.43% Upside
Average Price Target
The 12-month price target for Green Thumb Industries Inc. is $17.00.

GTBIF SharesGrow Score Overview

80/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 93/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 63/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 45/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GTBIF

✓
VALUE Pass
93/100
GTBIF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $17, implying +137.4% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
GTBIF: +4.9%/yr revenue is, +121.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
GTBIF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet GTBIF: Debt-to-Equity (D/E) ratio 0.27 (conservative), Current ratio is 1.55 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
63/100
GTBIF: Gross margin is 48.9% (-0.6 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 63/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate GTBIF as buy (100%). Analyst consensus target is $17 (+137.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
~
INCOME Partial
45/100
GTBIF: Net profit margin is 9.9%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.63-10.43
Volume54.08K
Avg Volume (30D)590.96K
Market Cap$1.7B
Beta (1Y)0.85
Share Statistics
EPS (TTM)0.49
Shares Outstanding$233.87M
IPO Date2018-06-14
Employees4,900
CEOBenjamin Kovler
Financial Highlights & Ratios
Revenue (TTM)$1.18B
Gross Profit$574.89M
EBITDA$485M
Net Income$116.15M
Operating Income$140.11M
Total Cash$274.3M
Total Debt$517.41M
Net Debt$243.11M
Total Assets$2.79B
Price / Earnings (P/E)14.6
Price / Sales (P/S)1.45
Analyst Forecast
1Y Price Target$17.00
Target High$17.00
Target Low$17.00
Upside+137.4%
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINCA39342L1085

Price Chart

Track all markets on TradingView
GTBIF
Green Thumb Industries Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
4.63 52WK RANGE 10.43

People Also View

CURLF
CURLF
Curaleaf Holdings, Inc.
$2.63
+8.72%
 TCNNF
TCNNF
Trulieve Cannabis Corp.
$6.73
+4.67%
 CRLBF
CRLBF
Cresco Labs Inc.
$0.98
+5.47%
 CWBHF
CWBHF
Charlotte's Web Holdings, Inc.
$0.62
-0.82%
 GRWG
GRWG
GrowGeneration Corp.
$1.10
+1.85%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message